Brno, Czechia

Vit Vsiansky

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Masarykova Univerzita. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vit Vsiansky. Retrieved from https://idiyas.com/inventor/vit-vsiansky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Vit Vsiansky: Innovator in Nuclease Inhibition

Introduction

Vit Vsiansky is a notable inventor based in Brno, Czech Republic. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit nucleases. His work is crucial for advancing treatments for various diseases.

Latest Patents

Vsiansky holds a patent for "Substituted propanamides as inhibitors of nucleases." This patent describes compounds represented by the structural formula (1), where R1, R2, R3, R4, R5, and R6 are identified as inhibitors of nucleases. These compounds are particularly useful in methods for treating and preventing proliferative diseases, neurodegenerative diseases, and other genomic instability-associated diseases. He has 1 patent to his name.

Career Highlights

Vit Vsiansky is affiliated with Masaryk University, where he conducts research and develops innovative solutions in his field. His academic background and research focus have positioned him as a key figure in biochemistry.

Collaborations

Vsiansky has collaborated with notable colleagues, including Kamil Paruch and Benoit Carbain. Their joint efforts contribute to the advancement of research in nucleic acid inhibition.

Conclusion

Vit Vsiansky's work in developing nucleic acid inhibitors represents a significant advancement in medical research. His contributions are vital for the future of treatments for various diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…